From the Guidelines
Your Immunohistochemistry (IHC) result is likely to show the expression of specific markers such as tryptase, CD117, CD25, and CD2, which are used to confirm the diagnosis of systemic mastocytosis (SM) and differentiate it from normal or reactive mast cells. To determine the IHC result, it is necessary to evaluate the expression of these markers in the tissue sample.
- Tryptase is considered the most sensitive marker for detecting small and/or immature mast cell infiltrates 1.
- CD117 is co-expressed with tryptase on normal mast cells, but immunostaining with these markers cannot distinguish between normal and neoplastic mast cells 1.
- Aberrant expression of CD2 and CD25 has been reported to be useful in differentiating mast cells in SM from normal/reactive mast cells in the bone marrow 1.
- CD25 is a more sensitive marker than CD2, as it is expressed in a higher percentage of mast cells in cases of indolent SM and advanced SM 1.
- The use of immunostaining for CD45 in combination with CD25 may specifically identify abnormal mast cells in patients with SM, although further studies are needed to confirm this finding 1. The IHC result will depend on the specific markers used and the presence or absence of these markers in the tissue sample. In the context of systemic mastocytosis, the IHC result is crucial for confirming the diagnosis and guiding treatment approaches. It is essential to interpret the IHC result in conjunction with other diagnostic criteria, such as clinical presentation, laboratory tests, and morphological evaluation of the bone marrow 1.
From the Research
Immunohistochemistry (IHC) Result
There are no research papers to assist in answering this question, as the provided studies focus on the cardiovascular toxicities of immune therapies for cancer and do not mention Immunohistochemistry (IHC) results.
Relevant Studies
- The studies provided discuss the diagnosis and management of immune checkpoint inhibitor cardiovascular toxicity 2, 3, 4, 5.
- They also touch on the cardiovascular toxicities of immune therapies for cancer, including myocarditis, arrhythmias, and conduction disease 4, 5.
- Additionally, the papers mention the importance of cardio-oncology in managing cancer therapy-related cardiotoxicities 6.
- However, none of the studies provide information on Immunohistochemistry (IHC) results.
Key Points
- Immune checkpoint inhibitors (ICIs) are associated with a risk of immune-related adverse events, including cardiovascular toxicity 2, 3, 4, 5.
- Cardio-oncology is a subspecialty that aims to manage cancer therapy-related cardiotoxicities 6.
- The provided studies do not discuss Immunohistochemistry (IHC) results, and therefore, cannot be used to answer the question.